Comparison of NY-ESO-1 expression in sarcoma tumors as assessed by PCR or IHC.
| Histological subtype | Case no. | NY-ESO-1 | |
| PCR a | IHC b | ||
| Gastrointestinal stromal tumor | 1 | +++ | 3/pos |
| 2 | - | 0/neg | |
| 3 | + | 2/pos | |
| 4 | - | 0/neg | |
| 5 | - | 0/neg | |
| Synovial sarcoma | 1 | +++ | 2-3/pos |
| 2 | +++ | 3/pos | |
| Uterine leiomyosarcoma | 1 | + | 1/neg |
| 2 | - | 1/neg | |
| 3 | - | 0/neg | |
| 4 | + | 2/pos | |
| 5 | +++ | 3/pos | |
| Leiomyosarcoma | 1 | - | 0/neg |
| 2 | - | 1/neg | |
| 3 | - | 0/neg | |
| 4 | - | 1/neg | |
| 5 | - | 0/neg | |
| 6 | - | 0/neg | |
| 7 | - | 1/neg | |
| Angiosarcoma | 1 | + | 1/neg |
| 2 | ++ | 2/pos | |
| 3 | - | 1/neg | |
| Malignant fibrous histiocytoma | 1 | ++ | 2/pos |
| 2 | - | 1/neg | |
| 3 | - | 1/neg | |
| 4 | - | 1/neg | |
| 5 | - | 0/neg | |
| Liposarcoma | 1 | - | 1/neg |
| 2 | +++ | 3/pos | |
| 3 | - | 0/neg | |
| 4 | - | 0/neg | |
| 5 | - | 0/neg | |
| 6 | - | nd | |
| Osteosarcoma | 1 | - | 0/neg |
| Chondrosarcoma | 1 | + | 0/neg |
| 2 | + | 1/neg | |
aNY-ESO-1 expression at the RNA level was assessed by semiquantitative RT-PCR. bNY-ESO-1 expression at the protein level was assessed by IHC using monoclonal antibody ES121 to NY-ESO-1. Scoring: 0, no positive cells; 1, rare and scattered positive cells; 2, < or = 50% positive cells; 3, >50% positive cells; nd, not done. Interpretation: pos, positive; neg, negative.